Anti-ENOX2 Rabbit Polyclonal Antibody for WB, IF/ICC, ELISA - Q16206

Core Product Specifications and Parameters

Biological Background: ENOX2 Function and Localization

• ENOX2 encodes ecto-NOX disulfide-thiol exchanger 2, also termed APK1, tNOX, and COVA1. Alternative splicing produces multiple isoforms.
• Functions as a terminal oxidase in the plasma membrane electron transport chain, cyclically catalyzing hydroquinone oxidation and protein disulfide-thiol interchange.
• The oscillating enzymatic activities (22‑minute period) are linked to the ultradian cellular clock and may regulate vesicle budding and cell enlargement.
• Subcellularly localized to the cell membrane and is also secreted into the extracellular space.
• Detected in the sera of patients with diverse cancers (breast, prostate, lung, ovarian, leukemias, lymphomas) but absent in healthy individuals, likely shed by cancer cells.
• Exhibits cell‑border expression on renal, kidney, and ovarian carcinoma cells, absent on surrounding non‑cancerous stromal cells.
• Keywords include glycoprotein and copper binding, indicating additional regulatory features.

Experimental Guidance and Technical Tips

• The immunogen spans amino acids 411–610 of human ENOX2, a region that may provide robust antibody accessibility for both denaturing and native detection methods.
• For Western blot, the predicted molecular weight is 70 kDa; consider including appropriate positive controls such as cancer cell lines.
• In IF/ICC, because ENOX2 is a membrane protein, permeabilization may be required for intracellular epitopes; fixation conditions should be optimized to preserve antigenicity.
• ELISA applications may benefit from pairing with a detection antibody that recognizes a non‑overlapping epitope; validate in the relevant sample system.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides a complete suite of IVD raw materials, including validated antibody pairs and optimized monoclonal/polyclonal antibodies like this anti‑ENOX2, to accelerate your cancer diagnostic assay development. In addition to this target, we supply bulk ancillary reagents and excel at sourcing rare‑target raw materials, ensuring a streamlined procurement journey from concept to clinic.